- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02019381
Study the Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism.
The Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism in Postmenopausal White Women.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The specific aims of this study proposal are to determine the following:
- To compare the two different intake guidelines for Calcium and Vitamin D Supplementation at its recommended tolerable upper limit on serum and urinary calcium in white postmenopausal Women.
- Compare the effects above mentioned two intake guidelines on Vitamin D metabolism [25(OH)D, 1,25(OH)2D] and bone turnover.
Participants will be randomly assigned to Group A or Group B based on different dosages of study medications.
Group A: 10,000 IU (International Units)Vitamin D + Placebo (sugar pill) 600IU Vitamin D + Two pills Calcium containing 600mg calcium each.
Group B: 600 IU Vitamin D + Placebo (sugar pill) 10,000 IU Vitamin D
+ Two pills Calcium containing 600mg calcium each.
In addition to the calcium supplements, they will guide to include approximately 800mg of calcium in their daily diet.
At visit 2, fasting blood and spot urine will be collected. A urinal will be dispensed for collection of 24-hour urine for urinary calcium to be brought in next day. Study medication will be dispensed and participants will be asked not to discard unused medications and to bring all study medications next study visit.
Visit 3, 4, 5, 6 will essentially be the same as visit 2, with subjects returning unused study medication and given new tablets each visit. Except on visit 6 no further study medications will be dispensed, after collecting the previous supply.
Food frequency questionnaires will be filled out at the initial visit and final visit. Diet will be assessed using 3-day diet history form and Nutrition Pro analysis software. Patients will be asked to refrain from taking other Vitamin D supplements and to continue their usual calcium intake.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
New York
-
Mineola, New York, États-Unis, 11501
- Winthrop University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Healthy White women aged 50 and older who have been postmenopausal for at least 2 year (i.e. absence of menstrual period for a period of 24 months or more).
- Willingness to discontinue self-administration of vitamin D and calcium supplements. Participants must be at least three months off supplements before starting the study.
- Willingness to take study medications and participate in study for one year.
- Written informed Consent Signed.
- Patients with hypertension and diabetes stable for last three months.
Exclusion Criteria:
- History of hypercalciuria (24-hour urinary calcium excretion >250 mg), hypercalcemia (serum calcium >10.6), nephrolithiasis and active sarcoidosis will be excluded.
- Serum 25-hydroxyvitamin D level >80 nmol/L or history of primary hyperparathyroidism.
- Dietary calcium intake of >2000mg/day will be excluded
- Use of medication that influences bone or vitamin D metabolism (e.g. anticonvulsant medications, glucocorticoids, Highly Active AntiRetroviral Therapy [AIDS treatment], antirejection medications, chronic use of steroids, high dose diuretics)
- Treatment with Hormone replacement therapy, Selective Estrogen Receptor Modulators, Calcitonin, Parathyroid hormone , androgens, bisphosphonates, phosphate or anabolic steroids 6 months prior to the study.
- Use of systemic steroids (oral or intravenous) within the last year at an average dose of more than 5mg/day of oral prednisone or an equivalent for a period of three months or more prior to screening.
- Chronic medical illness including Chronic liver disease, uncontrolled diabetes mellitus; recent history of myocardial infarction or heart failure; newly diagnosed or active malignancy; uncontrolled hypertension; obesity (BMI>35 kg/m2); malabsorption, anemia, leukemia, or other hematologic abnormalities; lupus, rheumatoid arthritis, sarcoidosis, or other rheumatologic disease; chronic kidney disease, metabolic bone disease.
- Unexplained weight loss of >15% during the previous year or history of anorexia nervosa
- > 1 pack per day tobacco use or > 2 alcoholic beverages per day
- Unwillingness to forego self-administration of vitamin D and calcium-containing supplements.
- Participation in another investigational trial in the past 30 days prior to the screening evaluation
- Significant deviation from normal in medical history, physical examination, or laboratory tests as evaluated by the primary investigator.
- Patients with unstable hypertension or diabetes.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Autre: Endocrine Society UL Dosage Vitamin D
Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines.
And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.
|
Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
1200mg of CaCO3 supplementation will be given to each participant in both groups
|
Autre: Institute of Medicine Dosage Vitamin D
Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits.
And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.
|
1200mg of CaCO3 supplementation will be given to each participant in both groups
IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Compare the effects of 10000 IU/day vitamin D plus 2,000 mg/day calcium versus 600 IU/day vitamin D plus 2,000 mg/day calcium on incidence of hypercalciuria (spot urine calcium:creatinine ratio, 24-hour urine calcium).
Délai: One year
|
Endocrine society has recommended tolerable upper limit or a dose with no adverse events as 10,000IU of Vitamin D and 2000 mg/day of calcium.
Our study will test the safety/ efficacy of this recommendation.
|
One year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Compare the effects of 10,000 IU/day vitamin D plus 2,000 mg/day calcium versus 600 IU/day vitamin D plus 2,000 mg/day calcium on vitamin D metabolism [25(OH)D, 1,25(OH)2D], and bone turnover.
Délai: One year
|
To test safety/efficacy of The Endocrine Society recommendations on Bone turnover.
|
One year
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: John Aloia, MD, Winthrop UH
- Directeur d'études: Mageda Mikhail, MD, Winthrop UH
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 13005
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Delusion of Reference
-
Queens College, The City University of New YorkRecrutementPublication d'articles soumis à l'American Journal of Public HealthÉtats-Unis
-
Abramson Cancer Center of the University of PennsylvaniaRetiréPatients cancéreux subissant une greffe de cellules souches (RCT of ACP for Transplant)
-
Swansea UniversityComplétéA Bite of ACT '(BOA) Cours de psychoéducation en ligne sur la thérapie d'acceptation et d'engagement | Un contrôle de liste d'attenteRoyaume-Uni